{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:53:41Z","timestamp":1791222821929,"version":"4.1.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T00:00:00Z","timestamp":1451433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0145772","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T18:44:19Z","timestamp":1451501059000},"page":"e0145772","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":83,"title":["HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing"],"prefix":"10.1371","volume":"10","author":[{"given":"Soo-Yon","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Raizes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert U.","family":"Van Zyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raph L.","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias F.","family":"Rinke de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole L.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Zeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Schapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avelin F.","family":"Aghokeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulio","family":"De Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M. J.","family":"Wensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel E.","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas D.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Fitzgibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bertagnolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/COH.0b013e3283637f7a","article-title":"Prevention of mother-to-child HIV transmission within the continuum of maternal, newborn, and child health services","volume":"8","author":"BH Chi","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"e1001245","DOI":"10.1371\/journal.pmed.1001245","article-title":"HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa","volume":"9","author":"JW Eaton","year":"2012","journal-title":"PLoS Med"},{"issue":"6122","key":"ref3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1126\/science.1230413","article-title":"Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment","volume":"339","author":"J Bor","year":"2013","journal-title":"Science"},{"issue":"6122","key":"ref4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.1228160","article-title":"High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa","volume":"339","author":"F Tanser","year":"2013","journal-title":"Science"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2010.993","article-title":"Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs","volume":"304","author":"CB Holmes","year":"2010","journal-title":"JAMA"},{"key":"ref6","unstructured":"HIV\/AIDS Programme World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013."},{"key":"ref7","unstructured":"HIV\/AIDS Programme World Health Organization. WHO HIV Drug Resistance Report 2012. 2012."},{"issue":"Suppl 2","key":"ref8","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jit121","article-title":"The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings","volume":"207","author":"S Bertagnolio","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","volume":"10","author":"RE Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2471\/BLT.12.112946","article-title":"Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review","volume":"91","author":"JH McMahon","year":"2013","journal-title":"Bull World Health Organ"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/cit627","article-title":"Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia","volume":"58","author":"AF Aghokeng","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"KM Stadeli","year":"2013","journal-title":"Antivir Ther"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"RK Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref14","first-page":"17","article-title":"Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world","volume":"14","author":"D Frentz","year":"2012","journal-title":"AIDS Rev"},{"issue":"9849","key":"ref15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"RK Gupta","year":"2012","journal-title":"Lancet"},{"key":"ref16","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual patient and sequence-level meta-analysis","author":"SY Rhee","year":"2015","journal-title":"PLoS Med"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QAI.0b013e3181e544e0","article-title":"HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia","volume":"55","author":"RL Hamers","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"RL Hamers","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ref19","first-page":"642","article-title":"2014 Update of the drug resistance mutations in HIV-1","volume":"22","author":"AM Wensing","year":"2014","journal-title":"Top Antivir Med"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"e67188","DOI":"10.1371\/journal.pone.0067188","article-title":"Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens","volume":"8","author":"GU Van Zyl","year":"2013","journal-title":"PLoS One"},{"key":"ref21","unstructured":"Rivadeneira E, Devos J, Dzioban E, Ngeno B, Zhang G, Sebatier J, et al. High prevalence of L74V\/I mutations in Kenyan children with virological failure (abstract 52). International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge, June 3\u20137, 2014, Berlin, Germany. 2014."},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1545109709355828","article-title":"96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients","volume":"9","author":"DR Malan","year":"2010","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e31815ace6a","article-title":"Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients","volume":"47","author":"DR Malan","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/infdis\/jis613","article-title":"HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status","volume":"206","author":"K Mollan","year":"2012","journal-title":"J Infect Dis"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/AAC.00574-10","article-title":"HIV-1 protease mutations and protease inhibitor cross-resistance","volume":"54","author":"SY Rhee","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1128\/AAC.49.9.3816-3824.2005","article-title":"Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones","volume":"49","author":"S Weinheimer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/JCM.00593-14","article-title":"SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings","volume":"52","author":"AV Ritchie","year":"2014","journal-title":"J Clin Microbiol"},{"key":"ref28","unstructured":"Murtagh M, for UNITAID. HIV\/AIDS Diagnostic Technology Landscape 2014, 4th Edition. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/unitaidorg\/images\/marketdynamics\/publications\/UNITAID-HIV_Diagnostic_Landscape-4th_editionpdf\" xlink:type=\"simple\">http:\/\/unitaidorg\/images\/marketdynamics\/publications\/UNITAID-HIV_Diagnostic_Landscape-4th_editionpdf<\/ext-link>. 2014."},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/cid\/cit733","article-title":"Developments in CD4 and viral load monitoring in resource-limited settings","volume":"58","author":"CF Rowley","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/JCM.03325-14","article-title":"Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa","volume":"53","author":"L Scott","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31829f05ac","article-title":"Viral load monitoring as a tool to reinforce adherence: a systematic review","volume":"64","author":"K Bonner","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/QAI.0b013e318266ee3f","article-title":"Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program","volume":"61","author":"V Johnston","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa","volume":"49","author":"CJ Hoffmann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/tmi.12237","article-title":"Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study","volume":"19","author":"CJ Hoffmann","year":"2014","journal-title":"Trop Med Int Health"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/cid\/cit933","article-title":"High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy","volume":"58","author":"RK Gupta","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ref36","first-page":"112","article-title":"From TMC114 to darunavir: five years of data on efficacy","volume":"15","author":"JM Llibre","year":"2013","journal-title":"AIDS Rev"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.coviro.2013.08.007","article-title":"Recent trends in HIV-1 drug resistance","volume":"3","author":"JD Siliciano","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkr569","article-title":"Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir\/ritonavir as their first protease inhibitor","volume":"67","author":"TJ Barber","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref39","first-page":"2339","article-title":"Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study","volume":"68","author":"DI Dolling","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"DI Rosenbloom","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/cid\/ciu367","article-title":"Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens","volume":"59","author":"Y Zheng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-9-63","article-title":"Human Immunodeficiency Virus Gag and protease: partners in resistance","volume":"9","author":"A Fun","year":"2012","journal-title":"Retrovirology"},{"issue":"9","key":"ref43","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"SA Rabi","year":"2013","journal-title":"J Clin Invest"},{"key":"ref44","unstructured":"World Health Organization HIV\/AIDS Programme. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013."},{"key":"ref45","article-title":"Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol","author":"M Bronze","year":"2013","journal-title":"J Virol Methods"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1128\/JCM.00118-13","article-title":"A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only","volume":"51","author":"SC Aitken","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1128\/AAC.01490-15","article-title":"HIV Drug Resistance Testing by High-Multiplex &quot;Wide&quot; Sequencing on the MiSeq Instrument","volume":"59","author":"HR Lapointe","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/QAI.0000000000000312","article-title":"Oligonucleotide Ligation Assay Detects HIV Drug Resistance Associated With Virologic Failure Among Antiretroviral-Naive Adults in Kenya","volume":"67","author":"MH Chung","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref49","unstructured":"MacLeod I, Rowley CF, Essex M. Pan degenerate ampflification and adaptation for highly sensitive detection of ARV drug resistance [abstract 606]. Conference on Retroviruses and Opportunistic Infections. 2014."},{"key":"ref50","article-title":"Simultaneous Detection of Major Drug Resistance Mutations in the Protease and Reverse Transcriptase Genes for HIV-1 Subtype C Using a Multiplex Allele-specific (MAS) Assay","author":"G Zhang","year":"2013","journal-title":"J Clin Microbiol"},{"key":"ref51","article-title":"Genetic Variability of HIV-1 for Drug Resistance Assay Development","author":"DS Clutter","year":"2015","journal-title":"PLoS One, under review"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/JCM.39.2.454-459.2001","article-title":"Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy","volume":"39","author":"J Servais","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"8","key":"ref53","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1128\/JCM.37.8.2533-2537.1999","article-title":"Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms","volume":"37","author":"M Vahey","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"9639","key":"ref54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"JM Molina","year":"2008","journal-title":"Lancet"},{"key":"ref55","article-title":"Boosted Lopinavir- Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/QAI.0b013e31802e2940","article-title":"Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy","volume":"44","author":"O Karlstrom","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"18","key":"ref57","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/QAD.0b013e32835646e0","article-title":"Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study","volume":"26","author":"M Guiguet","year":"2012","journal-title":"AIDS"},{"issue":"15","key":"ref58","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/QAD.0000000000000407","article-title":"Simplification to atazanavir\/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results","volume":"28","author":"A Castagna","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis","volume":"59","author":"L Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref60","unstructured":"Barnhart M, Shelton JD. ARVs: The next generation. Going boldly together to new frontiers of HIV treatment. Global Health Science and Practice. 2015;<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ghspjournal.org\/content\/early\/2015\/01\/28\/GHSP-D-14-00243.full.pdf+html\" xlink:type=\"simple\">http:\/\/www.ghspjournal.org\/content\/early\/2015\/01\/28\/GHSP-D-14-00243.full.pdf+html<\/ext-link>."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0145772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T11:07:50Z","timestamp":1599995270000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0145772"}},"subtitle":[],"editor":[{"given":"Paul Richard","family":"Harrigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,30]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0145772","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,30]]}}}